This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove 2040 Remove Research and Development Remove Safety Related Topics
Clinical Trials Epilepsy Chronic Pain Data Treatment Conditions CBD Therapy Pharmaceutical Events More Related Topics >
article thumbnail

MyMD Pharmaceuticals President Chris Chapman, M.D. Named Medical Honoree of the Year by the Arthritis Foundation

Cannabis Law Report

OCTOBER 26, 2021

MyMD’s lead drug candidate, MYMD-1, is being developed to target aging and related diseases along with autoimmune diseases including rheumatoid arthritis. MyMD’s lead drug candidate, MYMD-1, is being developed to target aging, aging-related diseases, and autoimmune diseases including rheumatoid arthritis. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52
Pharmaceutical Clinical Trials Research and Development Therapy 52
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 24,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024